|Dr. Henry H. Ji Ph.D.||Co-Founder, Chief Exec. Officer, Pres and Director||800k||N/A||53|
|Dr. Jeffrey Su Ph.D.||Chief Operating Officer and Exec. VP||514k||N/A||53|
|Mr. George K. Ng Esq., J.D.||Chief Admin. Officer, Chief Legal Officer and Exec. VP||551.49k||N/A||43|
|Dr. Jerome Bernard Zeldis M.D., Ph.D.||Chief Medical Officer and Pres of Clinical Devel.||103.13k||N/A||67|
|Mr. Douglas J. Langston||VP of Fin.||275.45k||N/A||56|
Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases. The company offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain at end-stage disease. Its preclinical human therapeutic antibodies include antibody drug conjugates, bispecific approaches, and T-Cell Receptor, as well as Chimeric Antigen Receptor-T Cell (CAR-T) for adoptive cellular immunotherapy for the treatment of solid and liquid tumors. It is also involved in the development of T-007, an anti-CD38 CAR-T cellular therapy for the treatment of multiple myeloma, as well as for additional potential indications, such as amyloidosis and graft-versus-host disease; and T-009, an anti-CD123 CAR-T cellular therapy for the treatment of acute myelogenous leukemia. The company has license and collaboration agreement with Les Laboratoires Servier for the development, manufacture, and commercialization of products using its human immuno-oncology anti-PD-1 mAb STI-A1110. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Sorrento Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 9. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 10; Compensation: 9.